Deadline: 11-Mar-2025
The American Urological Association Education and Research, Inc. (AUAER) and Pfizer Medical Grants & Partnerships (GMGP) are collaborating to offer grant support to urology health institutions and organizations to identify gaps in patient care for individuals with advanced prostate cancer (APC) and develop solutions-based projects to address these gaps.
Pfizer and Astellas via the “Pfizer-Astellas Alliance” are collaborating to provide independent grant support in the area of prostate cancer. For all independent grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. The companies must not be involved in any aspect of project development, nor the conduct, of the independent education program.
This RFP is being issued by all three organizations. AUAER is the lead organization for review and evaluation of proposals. A review committee, led by AUAER, will make decisions on which proposals will receive funding. Grant funding and general oversight of the funded projects will be provided directly from Pfizer on behalf of the Pfizer-Astellas Alliance.
Factors
- Many factors contribute to the complexity of treating APC, including:
- Identifying patients who may be appropriate candidates for intensified or combination therapy.
- Coordinating care across multidisciplinary team members and locations of care.
- Integrating rapidly advancing treatment options, including access to biomarker and genetic testing, and next generation imaging.
- Effectively sequencing therapies to treat APC.
- Introducing appropriate treatment intensification for patients with APC.
- Appropriately managing toxicities of approved therapies.
- Navigating the discrepancies between national treatment guidelines.
- The complexity of ensuring an adequate health care workforce, which often results in patient access issues.
Funding Information
- The total available budget related to this RFP is $1.5M.
- Individual projects requesting up to $250,000 will be considered.
- 2 years maximum: June 2025 – May 2027 (proposed start and end dates are approximate and may be adjusted).
Eligible Costs
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
Eligible Projects
- AUAER and Pfizer are interested in funding projects that meet one or more of the following:
- Foster multidisciplinary team involvement, including advanced practice providers (APPs) and genetic counselors, to enhance shared decision-making with patients.
- Optimize referral processes from urology to medical oncology.
- Improve therapy management.
- Sequencing strategies in urology/oncology practices, including combination approaches and integration of new treatments (e.g., PARPi).]
- Develop systematic approaches to conducting biomarker and genetic testing for patients.
- Improve access to treatment and diagnostics through improving adherence to AUA and NCCN Guidelines.
- Patient follow-up and close collaboration with Primary Care Physicians, who often monitor patients for PSA post- and during treatment.
Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals.
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions, organizations, and associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead or an authorized designee of such an individual (e.g., the Project Lead’s grant/research coordinator).
- The Project Lead must be an employee or contractor of the requesting organization.
- The requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution before applying. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
- Urology and urologic oncology health centers, institutions, and organizations are invited to submit grant applications for quality improvement projects that outline a planned process and methodology for improving APC care.
For more information, visit AUAER.
